Dear Colleagues,

Disturbances in the normal cellular redox state, caused by an increase of reactive oxygen species (ROS) and/or insufficient production of antioxidants, can cause oxidative stress. Oxidative stress can lead to indiscriminate damage to all cellular constituents, including DNA, proteins, and membranes, and it is strongly associated with a number of chronic pathologies, including cardiovascular and neurodegenerative diseases, among many others. Oxidative stress may also be involved in the response to both pharmacological and non-pharmacological treatments. In particular, patients widely vary in drug response in terms of both efficacy and tolerability. For example, only about 50% of patients treated with commonly used antihypertensive medications achieve adequate blood pressure control. The study of the variability of the response to drug dependence given an individual genetic background is the area of interest of pharmacogenetics.

Several polymorphisms in genes involved in redox homeostasis encoding for both pro-oxidant and anti-oxidant proteins are now recognized as modulators of the response to phytochemicals or drugs with antioxidant properties, as well as to oxidative stress produced by drug use.

This Special Issue of the Journal of Personalized Medicine aims to highlight the current state of the knowledge of the application and opportunities to apply the precepts of pharmacogenetics to understand the complex role of ROS in human pathophysiology and to improve patient care using a personalized approach.

We invite investigators to contribute both original research and reviews focusing on this field.

Prof. Dr.Amelia Filippelli
Dr. Valeria Conti
Dr. Graziamaria Corbi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• Oxidative stress
• Parmacogenetics
• Pharmacogenomics
• Personalized medicine
• Reactive Oxygen Species
• Drug response variability